Business
Why IPO Stock LB Pharmaceuticals Tripled In A Year
Small biotech LB Pharmaceuticals (LBRX) is on a tear. The IPO stock has more than tripled in under a year as investors watch its efforts to take on Bristol Myers Squibb (BMY) and Johnson & Johnson (JNJ). The New York-based company has one drug: an oral formulation of the antipsychotic benzamide. It calls the drug LB-102. Benzamide is approved in…
Copyright ©2026 Investor’s Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8
You must be logged in to post a comment Login